Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
Parameters | No. | Mean ± SEM | Median | p | |
Agea | |||||
≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
> 54 | 49 | 163.83 ± 8.86 | 165 | ||
Gendera | |||||
Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
Female | 15 | 164.33 ± 13.21 | 160 | ||
Tumor siteb | |||||
Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
Tongue | 7 | 170.36 ± 25.33 | 170 | ||
Others | 14 | 165.36 ± 19.25 | 171 | ||
Histological gradeb | |||||
Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
Moderate | 71 | 156.13 ± 8.35 | 160 | ||
Poor | 6 | 167.08 ± 30.81 | 183 | ||
Stagea | |||||
I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
III–IV | 56 | 178.13 ± 8.34 | 184 | ||
Tumor statusa | |||||
T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
Nodal metastasisa | |||||
Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
Present | 31 | 179.52 ± 12.64 | 180 | ||
Distant metastasisa | |||||
Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
236P - Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 03
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03